

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

\_\_\_\_\_  
Type or print name of person signing certification

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date

**PATENT**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

U. S. Patent No. : 7,541,033  
Issued: : June 2, 2009  
First Applicant : DICKINSON, Craig Duane  
Serial No. : 10/542,508  
International Application Date : January 21, 2004  
National Entry Date: July 15, 2005  
Entitled : HUMANIZED ANTI-IL-1 $\beta$  ANTIBODIES  
Docket No. : X-15950

**REQUEST FOR CERTIFICATE OF CORRECTION**  
**UNDER 37 C.F.R. 1.323**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The patentees of the above-identified patent respectfully request that you issue a Certificate of Correction to correct certain errors in the patent.

Some of the errors are typographical and were made inadvertently. The remaining errors occurred during the printing of the patent.

Application No.: 10/542,508  
Docket No.: X15950

Please charge any fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840.

Respectfully submitted,

/Andrea M. Castetter/  
Andrea M. Castetter  
Agent for Applicantss  
Registration No. 63,964  
Phone: 317-433-0895

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

June 11, 2010

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

Page 1 of 1

PATENT NO. : 7,541,033  
APPLICATION NO.: 10/542,508  
DATED : June 2, 2009  
INVENTOR(S) : Craig Duane Dickinson et al

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

The priority is not correctly reflected on the face of the patent.

Insert on Front Page of patent:

**Related U.S. Application Data**

**Provisional application No. 60/442,798 filed on Jan. 24, 2003**

Insert on page 1 of specification located underneath the title:

**This is a national phase application, under 35 USC 371, for PCT/US04/000119, filed 21 January 2004, which claims the benefit, under 34 USC 119(e), of US provisional application 60/442,798, filed on 24 January 2003.**

**MAILING ADDRESS OF SENDER:**

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288